741 related articles for article (PubMed ID: 12799213)
1. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity.
Robak E; Woźniacka A; Sysa-Jedrzejowska A; Stepień H; Robak T
Eur Cytokine Netw; 2001; 12(3):445-52. PubMed ID: 11566625
[TBL] [Abstract][Full Text] [Related]
3. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Urbańska-Ryś H; Robak T
Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
5. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
6. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.
Gora-Tybor J; Blonski JZ; Robak T
Mediators Inflamm; 2003 Jun; 12(3):167-71. PubMed ID: 12857600
[TBL] [Abstract][Full Text] [Related]
7. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
8. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
[TBL] [Abstract][Full Text] [Related]
9. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity.
Anagnostopoulos A; Eleftherakis-Papaiakovou V; Kastritis E; Tsionos K; Bamias A; Meletis J; Dimopoulos MA; Terpos E
Br J Haematol; 2007 Jun; 137(6):560-8. PubMed ID: 17451406
[TBL] [Abstract][Full Text] [Related]
12. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
Tabone MD; Landman-Parker J; Arcil B; Coudert MC; Gerota I; Benbunan M; Leverger G; Dosquet C
Clin Cancer Res; 2001 Mar; 7(3):538-43. PubMed ID: 11297245
[TBL] [Abstract][Full Text] [Related]
13. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
[TBL] [Abstract][Full Text] [Related]
14. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
15. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN
Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.
Sezer O; Jakob C; Eucker J; Niemöller K; Gatz F; Wernecke K; Possinger K
Eur J Haematol; 2001 Feb; 66(2):83-8. PubMed ID: 11168514
[TBL] [Abstract][Full Text] [Related]
17. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
18. Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery.
Curigliano G; Petit JY; Bertolini F; Colleoni M; Peruzzotti G; de Braud F; Gandini S; Giraldo A; Martella S; Orlando L; Munzone E; Pietri E; Luini A; Goldhirsch A
Breast Cancer Res Treat; 2005 Sep; 93(1):35-40. PubMed ID: 16184456
[TBL] [Abstract][Full Text] [Related]
19. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
[TBL] [Abstract][Full Text] [Related]
20. Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy.
Andrys C; Borska L; Pohl D; Fiala Z; Hamakova K; Krejsek J
Arch Dermatol Res; 2007 Mar; 298(10):479-83. PubMed ID: 17221216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
